Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 and Sintilimab for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
NCT05890742Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2023
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310 in colon cancer, sponsored by Innovent Biologics. Started May 2023; status: active, not recruiting.
02
Drugs
IBI310
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05890742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890742.